Crohn's Disease

Hispanic patients treated with biologic agents for inflammatory bowel diseases face a greater risk for hospitalization, surgery and infections compared with non-Hispanic patients, according to a study in Clinical Gastroenterology and Hepatology.

Patients with inflammatory bowel disease were nine times more likely to develop depression, and their unaffected siblings twice as likely to develop depression, according to a study in the Journal of Gastroenterology and Hepatology.

Healio presents the top peer-tested articles from June, which include updates on the acute hepatitis outbreak in children, FDA approval of Skyrizi for Crohn’s disease, investigational care of patients with chronic constipation and more.

In a Healio video exclusive, Remo Panaccione, MD, discusses results from long-term, pooled analyses of adult patients treated with ustekinumab for inflammatory bowel disease.

During the International Liver Congress, experts provided updates on the growing outbreak of acute, severe hepatitis of unknown etiology in children.

Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet.

Here are Healio’s top 10 peer-tested articles from Digestive Disease Week 2022, which highlight research on restrictive diets, gallstone disease, dog ownership and Crohn’s disease, COVID-19 antibody response and more.

The FDA has approved AbbVie’s Skyrizi for the treatment of adults with moderately to severely active Crohn’s disease, according to a company press release.

SAN DIEGO — Patients with inflammatory bowel disease experienced reduced symptom frequency and severity after a third SARS-CoV-2 mRNA vaccine compared with after a second, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — Seroconversion rates and antibody response significantly increased after a third dose of SARS-CoV-2 vaccine in patients with inflammatory bowel disease, according to a presenter at Digestive Disease Week 2022.